HISAMITSU PHARMACEUTICAL CO.,INC. [4530.T]
TOKYO, Apr 13 (Pulse News Wire) – Hisamitsu Pharmaceutical Co.,Inc. (4530.T) reported consolidated results for fiscal year 2026 ending February.
Revenue was ¥160 billion (+4.5% YoY). operating profit was ¥17,917 million (-5.2%).
Net profit attributable to shareholders was ¥19,160 million (-11.9%). Total assets stood at ¥370 billion with an equity ratio of 79.4%.
The full-year forecast for the current fiscal year is revenue of ¥100 billion (+1.1%).
Financial results — FY2026/2 (consolidated)
| Metric | Current | YoY |
|---|---|---|
| Revenue | ¥163,024M | +4.5% |
| Operating profit | ¥17,917M | -5.2% |
| Net profit | ¥19,160M | -11.9% |
Source: TDNet filing · Figures in millions of yen
🟢 Confidence: High AI-translated content.